U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly and Company (LLY) said on Monday that the highest approved doses of its weight-loss drug Zepbound will soon be ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...